MediciNova

Yahoo Finance • 4 days ago

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced... Full story

Yahoo Finance • last month

Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Mizuho upgraded MongoDB (MDB) to Outper... Full story

Yahoo Finance • 2 months ago

MediciNova to Participate at the 38th Annual ROTH Conference

MediciNova, Inc. LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)... Full story

Yahoo Finance • 4 months ago

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MediciNova, Inc. LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), t... Full story

Yahoo Finance • 5 months ago

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an upda... Full story

Yahoo Finance • 5 months ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to ann... Full story

Yahoo Finance • 6 months ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that th... Full story

Yahoo Finance • 6 months ago

3 Penny Stocks With Market Caps Over $80M To Consider

As the United States stock market continues to post gains, boosted by strong performances from tech giants like Amazon, investors are exploring diverse opportunities across various sectors. Penny stocks, while often considered a relic of p... Full story

Yahoo Finance • 6 months ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the pub... Full story

Yahoo Finance • 7 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”),... Full story

Yahoo Finance • 7 months ago

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

MediciNova, Inc. ~Patient Recruitment Closed~ LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock... Full story

Yahoo Finance • 8 months ago

MediciNova Provides Shareholder Update on Key Developments

LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”),... Full story

Yahoo Finance • 8 months ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”),... Full story

Yahoo Finance • 8 months ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that i... Full story

Yahoo Finance • 8 months ago

MediciNova files to sell 25M shares of common stock for holders

* MediciNova (NASDAQ:MNOV [https://seekingalpha.com/symbol/MNOV]) filed to sell 25M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10335798] MORE ON MEDICINOVA * Seeking Alpha’s Quant Rating on Medici... Full story

Yahoo Finance • 9 months ago

MediciNova signs standby equity purchase agreement for up to $30M

* MediciNova (NASDAQ:MNOV [https://seekingalpha.com/symbol/MNOV]) and the Standard Market of the Tokyo Stock Exchange on Thursday announced [https://seekingalpha.com/pr/20185946-medicinova-announces-signing-of-a-standby-equity-purchase-a... Full story

Yahoo Finance • 9 months ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), t... Full story

Yahoo Finance • last year

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces... Full story

Yahoo Finance • last year

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced... Full story

Yahoo Finance • 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced t... Full story